Program
pegfilgrastim
Also written as “Pegfilgrastim”, “CHS-1701” and “QL0605(PEG-rhG-CSF)”.
Its studies are mostly in Neutropenia · Breast Neoplasms · Lymphoma, Non-Hodgkin · Lymphoma · Febrile Neutropenia, led by 21 companies.
Drug pagePegfilgrastim: every studyMany companies study it; this page follows only the 47 they lead. All 136 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 150 open or running | phase 4since Jun 21, 2005 | May 3, 2002 | none ahead |
| Dong-A STits history only | 30 open or running | phase 3since Jan 19, 2012 | Jan 19, 2012 | none ahead |
| Kyowa Kirinits history only | 30 open or running | phase 2since Aug 14, 2006 | Aug 14, 2006 | none ahead |
| Adello Biologicsits history only | 20 open or running | phase 1since Apr 12, 2017 | Apr 12, 2017 | none ahead |
| Coherus Biosciences | 20 open or running | phase 1since Apr 8, 2015 | Apr 8, 2015 | none ahead |
| Fresenius Kabiits history only | 20 open or running | phase 1since Aug 14, 2017 | Aug 14, 2017 | none ahead |
| Hangzhou Jiuyuan Gene Engineeringits history only | 20 open or running | phase 2since Aug 6, 2013 | Jul 2, 2012 | none ahead |
| Intas Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 8, 2019 | Jul 8, 2019 | none ahead |
| Merckleits history only | 20 open or running | phase 1since Apr 18, 2012 | Apr 18, 2012 | none ahead |
| Mundipharmaits history only | 20 open or running | phase 1since Dec 10, 2015 | Dec 10, 2015 | none ahead |
| Qilu Pharmaceuticalits history only | 21 open or running | phase 4since Sep 25, 2024 | Nov 9, 2020 | none ahead |
| Amneal Pharmaceuticalsits history only | 10 open or running | phase 1since Feb 6, 2026 | Feb 6, 2026 | none ahead |
| Coherus Oncologyits history only | 10 open or running | phase 1since Mar 2, 2015 | Mar 2, 2015 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 1since Oct 20, 2015 | Oct 20, 2015 | none ahead |
| GC Biopharmaits history only | 10 open or running | phase 3since Feb 6, 2011 | Feb 6, 2011 | none ahead |
| Gedeon Richter Plc.its history only | 10 open or running | phase 1since Apr 26, 2017 | Apr 26, 2017 | none ahead |
| Gema Biotechits history only | 10 open or running | phase 3since Feb 15, 2016 | Feb 15, 2016 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 4since May 16, 2016 | May 16, 2016 | none ahead |
| Kexing Biopharmits history only | 11 open or running | phase 3since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Nanogen Pharmaceutical Biotechnology Joint Stockits history only | 10 open or running | phase 1since Dec 12, 2017 | Dec 12, 2017 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jan 21, 2014 | Jan 21, 2014 | none ahead |
Also a collaborator on its studies: Lambda Therapeutic Research, Celerion and Symyoo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Coherus Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 8, 2015First study: phase 1 study in Immunity, HumoralFirst studyNCT02418104 · 303 enrolled · United States
- Jan 5, 2016Phase 1 study in HealthyNCT02650973 · 122 enrolled · United States
TargetBeta
“A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity”NCIt, by rule
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule
Studies
All 2 Coherus Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02650973Healthy · United States | 1 | Completed | Jun 2016 | 122 |
| NCT02418104Immunity, Humoral · United States | 1 | Completed | Dec 2015 | 303 |
How it is read
Names in the registry
- “Pegfilgrastim”, 13 entries
- “pegfilgrastim”, 12 entries
- “CHS-1701”, 3 entries
- “QL0605(PEG-rhG-CSF)”, 2 entries
- “lipegfilgrastim”, 2 entries
Codes read as this program: TPI120.
Conditions, from the studies’ own filings
- Neutropenia, 14 studies
- Breast Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 4 studies
- Lymphoma, 2 studies
- Febrile Neutropenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.